Barbara Kosacz - 23 Jun 2026 Form 4 Insider Report for LeonaBio, Inc. (LONA)

Reporting relationship: Director
Issuer ticker: LONA
Reported as of: 23 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Jun 2026, 18:29:35 UTC
Prior SEC filing: 26 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Worthington, Attorney in fact for Barbara Kosacz

Key filing fact

Barbara Kosacz filed Form 4 for LeonaBio, Inc. (LONA) on 24 Jun 2026.

Key facts

This page summarizes Barbara Kosacz's Form 4 filing for LeonaBio, Inc. (LONA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Jun 2026, 18:29.

Change

Previous filing in this sequence was filed on 26 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001763316 Primary reporting owner

Kosacz Barbara

Relationship: Director
Address: C/O LEONABIO, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Signature: /s/ Mark Worthington, Attorney in fact for Barbara Kosacz
Signature date: 24 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LONA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +28,000
Change %
Price: $0.000000^*
Shares after: 28,000
Date: 23 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 28,000
Exercise price: $8.35
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.